CA2535762A1 - Methods for inhibiting tumor cell proliferation - Google Patents
Methods for inhibiting tumor cell proliferation Download PDFInfo
- Publication number
- CA2535762A1 CA2535762A1 CA002535762A CA2535762A CA2535762A1 CA 2535762 A1 CA2535762 A1 CA 2535762A1 CA 002535762 A CA002535762 A CA 002535762A CA 2535762 A CA2535762 A CA 2535762A CA 2535762 A1 CA2535762 A1 CA 2535762A1
- Authority
- CA
- Canada
- Prior art keywords
- cell
- stat3
- platinum
- cells
- isscpa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 22
- 210000004881 tumor cell Anatomy 0.000 title claims description 14
- 230000002401 inhibitory effect Effects 0.000 title claims description 10
- 230000004663 cell proliferation Effects 0.000 title description 6
- 210000004027 cell Anatomy 0.000 claims description 60
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 37
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 229910052697 platinum Inorganic materials 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 102000004495 STAT3 Transcription Factor Human genes 0.000 claims description 3
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 241000282693 Cercopithecidae Species 0.000 claims description 2
- 241000283073 Equus caballus Species 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 claims description 2
- 241000282577 Pan troglodytes Species 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 210000005260 human cell Anatomy 0.000 claims 1
- 150000003057 platinum Chemical class 0.000 abstract description 48
- 230000005764 inhibitory process Effects 0.000 abstract description 9
- FLEHQRTTWKDNGI-WSGFCWAJSA-N (1r,3r)-5-[(2e)-2-[(1r,3as,7ar)-1-[(2r)-5-(cyclopropylamino)pentan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-2-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C1C[C@@H](O)C(=C)[C@H](O)C1)C)CCNC1CC1 FLEHQRTTWKDNGI-WSGFCWAJSA-N 0.000 abstract description 5
- 101100112225 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) cpa-1 gene Proteins 0.000 abstract description 5
- 230000008827 biological function Effects 0.000 abstract 1
- 101150099493 STAT3 gene Proteins 0.000 description 57
- 230000000694 effects Effects 0.000 description 38
- 150000001875 compounds Chemical class 0.000 description 18
- 210000002950 fibroblast Anatomy 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 239000000284 extract Substances 0.000 description 14
- 230000004568 DNA-binding Effects 0.000 description 11
- 230000006907 apoptotic process Effects 0.000 description 11
- FBEIPJNQGITEBL-UHFFFAOYSA-J tetrachloroplatinum Chemical compound Cl[Pt](Cl)(Cl)Cl FBEIPJNQGITEBL-UHFFFAOYSA-J 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 10
- 108010058765 Oncogene Protein pp60(v-src) Proteins 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 150000003058 platinum compounds Chemical class 0.000 description 8
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 239000002751 oligonucleotide probe Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 208000029742 colonic neoplasm Diseases 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 108091054455 MAP kinase family Proteins 0.000 description 5
- 102000043136 MAP kinase family Human genes 0.000 description 5
- 102000000887 Transcription factor STAT Human genes 0.000 description 5
- 108050007918 Transcription factor STAT Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 5
- 229960004316 cisplatin Drugs 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 5
- 102400001368 Epidermal growth factor Human genes 0.000 description 4
- 101800003838 Epidermal growth factor Proteins 0.000 description 4
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 4
- 101000904152 Homo sapiens Transcription factor E2F1 Proteins 0.000 description 4
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 4
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 4
- 102100024026 Transcription factor E2F1 Human genes 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229940116977 epidermal growth factor Drugs 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 238000012287 DNA Binding Assay Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000013042 tunel staining Methods 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108010052090 Renilla Luciferases Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 108020001096 dihydrofolate reductase Proteins 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- -1 ovarian Diseases 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000015617 Janus Kinases Human genes 0.000 description 1
- 108010024121 Janus Kinases Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101150024075 Mapk1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 229910019029 PtCl4 Inorganic materials 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 102000001712 STAT5 Transcription Factor Human genes 0.000 description 1
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 101100311214 Xenopus laevis stat3.1 gene Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 210000000069 breast epithelial cell Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007916 intrasternal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- NDBYXKQCPYUOMI-UHFFFAOYSA-N platinum(4+) Chemical compound [Pt+4] NDBYXKQCPYUOMI-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 108091005990 tyrosine-phosphorylated proteins Proteins 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48122603P | 2003-08-13 | 2003-08-13 | |
| US60/481,226 | 2003-08-13 | ||
| US51558003P | 2003-10-30 | 2003-10-30 | |
| US60/515,580 | 2003-10-30 | ||
| US51994303P | 2003-11-14 | 2003-11-14 | |
| US60/519,943 | 2003-11-14 | ||
| US52529503P | 2003-11-25 | 2003-11-25 | |
| US60/525,295 | 2003-11-25 | ||
| PCT/US2004/026392 WO2005023824A2 (en) | 2003-08-13 | 2004-08-13 | Methods for inhibiting tumor cell proliferation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2535762A1 true CA2535762A1 (en) | 2005-03-17 |
Family
ID=34199238
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002535762A Abandoned CA2535762A1 (en) | 2003-08-13 | 2004-08-13 | Methods for inhibiting tumor cell proliferation |
| CA002535584A Abandoned CA2535584A1 (en) | 2003-08-13 | 2004-08-13 | Platinum complexes for the treatment of tumors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002535584A Abandoned CA2535584A1 (en) | 2003-08-13 | 2004-08-13 | Platinum complexes for the treatment of tumors |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US7238372B2 (enExample) |
| EP (2) | EP1675864B1 (enExample) |
| JP (2) | JP2007502777A (enExample) |
| AT (2) | ATE453653T1 (enExample) |
| AU (3) | AU2004270655B2 (enExample) |
| CA (2) | CA2535762A1 (enExample) |
| DE (2) | DE602004024909D1 (enExample) |
| WO (2) | WO2005023824A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005023824A2 (en) | 2003-08-13 | 2005-03-17 | University Of South Florida | Methods for inhibiting tumor cell proliferation |
| US20050288365A1 (en) * | 2004-01-06 | 2005-12-29 | Heidi Kay | Platinum complexes and methods for inhibiting tumor cell proliferation |
| EP1748772A2 (en) * | 2004-04-09 | 2007-02-07 | University Of South Florida | Combination therapies for cancer and proliferative angiopathies |
| WO2007008247A2 (en) | 2004-11-10 | 2007-01-18 | University Of South Florida | Platinum complexes for targeted drug delivery |
| US7951374B2 (en) | 2004-12-14 | 2011-05-31 | University Of South Florida | Methods for inhibiting STAT3 signaling in immune cells |
| DE102004060934A1 (de) * | 2004-12-17 | 2006-06-29 | Wacker Chemie Ag | Vernetzbare Polyorganosiloxanmassen |
| JP5193032B2 (ja) * | 2005-06-30 | 2013-05-08 | バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド | モノアゾールリガンド白金類似体 |
| US20100190180A1 (en) * | 2005-07-06 | 2010-07-29 | Heidi Kay | Materials and Methods for Screening, Diagnosis and Prognosis of Conditions Associated With Stat Protein Expression |
| WO2007013946A2 (en) * | 2005-07-20 | 2007-02-01 | University Of South Florida | Method of predicting responsiveness to chemotherapy and selecting treatments |
| WO2007047623A2 (en) * | 2005-10-14 | 2007-04-26 | University Of South Florida | Methods of inhibiting cell growth and methods of enhancing radiation responses |
| DE102006040647A1 (de) * | 2006-08-30 | 2008-03-13 | Robert Bosch Gmbh | Handwerkzeugmaschine |
| US8026382B2 (en) | 2007-05-18 | 2011-09-27 | Heidi Kay | Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods |
| US8895610B1 (en) | 2007-05-18 | 2014-11-25 | Heldi Kay | Platinum (IV) compounds targeting zinc finger domains |
| CA2691047A1 (en) * | 2007-06-18 | 2008-12-24 | Platco Technologies (Proprietary) Limited | Platinum (iv) complexes |
| CA2736563C (en) * | 2007-09-10 | 2016-01-26 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
| WO2010067335A1 (en) | 2008-12-12 | 2010-06-17 | Platco Technologies (Proprietary) Limited | Platinum (iv) complexes for use in the treatment of proliferative diseases such as cancer |
| DK3012329T3 (da) | 2010-06-18 | 2017-11-20 | Myriad Genetics Inc | Fremgangsmåder og materialer til at vurdere tab af heterozygositet |
| ES2588979T3 (es) | 2010-08-24 | 2016-11-08 | Dana-Farber Cancer Institute, Inc. | Procedimientos para la predicción de una respuesta contra el cáncer |
| EP2721181B1 (en) | 2011-06-17 | 2019-12-18 | Myriad Genetics, Inc. | Methods and materials for assessing allelic imbalance |
| RU2491936C2 (ru) * | 2011-07-11 | 2013-09-10 | Борис Николаевич Анисимов | Способ комплексного лечения больных паразитарными заболеваниями |
| EP4497824A3 (en) | 2011-12-21 | 2025-04-16 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
| AU2013226400B2 (en) | 2012-02-23 | 2018-09-06 | Dana-Farber Cancer Institute, Inc. | Methods for predicting anti-cancer response |
| ES2658867T3 (es) | 2012-06-07 | 2018-03-12 | Institut Curie | Métodos para detectar la inactivación de la ruta de recombinación homóloga (BRCA1/2) en tumores humanos |
| WO2014160080A1 (en) | 2013-03-14 | 2014-10-02 | Children's Medical Center Corporation | Cancer diagnosis, treatment selection and treatment |
| US10766915B2 (en) | 2013-03-15 | 2020-09-08 | Sherri Ann McFARLAND | Metal-based coordination complexes as photodynamic compounds and their use |
| WO2014165785A2 (en) | 2013-04-05 | 2014-10-09 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
| WO2014198140A1 (zh) * | 2013-06-13 | 2014-12-18 | 上海医药工业研究院 | 一种铂（ⅱ）配合物、其制备方法、药物组合物及应用 |
| WO2015013565A1 (en) * | 2013-07-25 | 2015-01-29 | Nemucore Medical Innovations, Inc. | Platinum derivatives for hydrophobic formulations |
| ES2909899T3 (es) | 2013-12-09 | 2022-05-10 | Inst Curie | Métodos para detectar inactivación de la ruta de recombinación homóloga (BRCA1/2) en tumores humanos |
| DK3180447T3 (da) | 2014-08-15 | 2020-06-15 | Myriad Genetics Inc | Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens |
| BR112017027285A2 (pt) | 2015-06-19 | 2018-09-11 | Syn Nat Products Entpr Llc | ?cocristal, composição farmacêutica e método para o tratamento de uma doença? |
| KR20180014834A (ko) | 2015-06-19 | 2018-02-09 | 신-낫 프로덕츠 엔터프라이즈 엘엘씨 | 카보플라틴을 함유하는 조성물 및 용도 |
| CA2989001A1 (en) | 2015-06-25 | 2016-12-29 | Syn-Nat Products Enterprise LLC | Pharmaceutical co-crystal composition and use thereof |
| US11299469B2 (en) | 2016-11-29 | 2022-04-12 | Sumitomo Dainippon Pharma Oncology, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| US20200361973A1 (en) | 2017-11-21 | 2020-11-19 | Medoncare Pharmaceutical Co., Ltd. | Combination product comprising dicycloplatin and preparation method and use thereof |
| CN112175014B (zh) * | 2020-10-10 | 2021-08-20 | 中国药科大学 | 一种一氧化氮供体型四价铂衍生物、制备方法及其医药用途 |
| EP4141127B1 (en) | 2021-08-30 | 2024-10-09 | Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln | Method for assessing homologous recombination deficiency in ovarian cancer cells |
| WO2024063828A1 (en) | 2022-09-21 | 2024-03-28 | Oracle International Corporation | Expert-optimal correlation: contamination factor identification for unsupervised anomaly detection |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4177263A (en) * | 1972-02-28 | 1979-12-04 | Research Corporation | Anti-animal tumor method |
| GB1432563A (en) * | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum- co-ordination compounds |
| GR851932B (enExample) * | 1984-08-14 | 1985-12-13 | Engelhard Corp | |
| JPS6296A (ja) * | 1985-03-06 | 1987-01-06 | Sumitomo Pharmaceut Co Ltd | 脂溶性白金（２）錯体 |
| JPH01156989A (ja) * | 1987-09-25 | 1989-06-20 | Ss Pharmaceut Co Ltd | 新規白金錯体 |
| ES2063119T3 (es) * | 1988-02-02 | 1995-01-01 | Johnson Matthey Inc | Complejos de pt (iv). |
| JP3520367B2 (ja) * | 1994-12-22 | 2004-04-19 | 独立行政法人産業技術総合研究所 | 白金ニトロアンミン系錯体の製造方法 |
| DE69627641T2 (de) | 1995-02-28 | 2004-02-05 | Kidani, Yoshinori, Fujisawa | Platin(iv)-komplexe, verfahren zu ihrer herstellung und sie enthaltende carcinostatische mittel |
| US5922689A (en) * | 1995-09-11 | 1999-07-13 | Unitech Pharmaceuticals, Inc. | Cisplatin analogs for cancer treatment |
| US5849790A (en) * | 1995-11-17 | 1998-12-15 | The University Of South Florida | (Mono) ethylenediaminenitroplatinum (IV) complexes with ligands of oxides of nitrogen as possible anti-tumor agents |
| US6145688A (en) * | 1996-07-17 | 2000-11-14 | Smith; James C. | Closure device for containers |
| US5977393A (en) | 1997-11-21 | 1999-11-02 | California Institute Of Technology | Schiff base derivatives of ruthenium and osmium olefin metathesis catalysts |
| KR100246722B1 (ko) * | 1997-12-30 | 2000-04-01 | 박호군 | 경구용 백금 착화합물 항암제 및 그 제조방법 |
| WO2000032235A1 (de) | 1998-11-26 | 2000-06-08 | Pentapharm Ag | Transportsystemkonjugate |
| JP2003525862A (ja) * | 1999-01-27 | 2003-09-02 | ザ ユニヴァーシティー オブ サウス フロリダ | ヒト癌の治療のためのｓｔａｔ３シグナル伝達の阻害 |
| US6511676B1 (en) * | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| US7034109B2 (en) | 2000-10-13 | 2006-04-25 | Christophe Bonny | Intracellular delivery of biological effectors |
| US7033597B2 (en) | 2000-10-13 | 2006-04-25 | Université de Lausanne | Intracellular delivery of biological effectors |
| US7638122B2 (en) * | 2003-03-07 | 2009-12-29 | University Of South Florida | Stat3 antagonists and their use as vaccines against cancer |
| WO2005002508A2 (en) * | 2003-06-11 | 2005-01-13 | Access Pharmaceuticals, Inc. | Macromolecular platinum chelates |
| WO2005023824A2 (en) | 2003-08-13 | 2005-03-17 | University Of South Florida | Methods for inhibiting tumor cell proliferation |
| US20050288365A1 (en) | 2004-01-06 | 2005-12-29 | Heidi Kay | Platinum complexes and methods for inhibiting tumor cell proliferation |
| WO2007008247A2 (en) | 2004-11-10 | 2007-01-18 | University Of South Florida | Platinum complexes for targeted drug delivery |
| US20100190180A1 (en) | 2005-07-06 | 2010-07-29 | Heidi Kay | Materials and Methods for Screening, Diagnosis and Prognosis of Conditions Associated With Stat Protein Expression |
-
2004
- 2004-08-13 WO PCT/US2004/026392 patent/WO2005023824A2/en not_active Ceased
- 2004-08-13 DE DE602004024909T patent/DE602004024909D1/de not_active Expired - Lifetime
- 2004-08-13 DE DE602004015811T patent/DE602004015811D1/de not_active Expired - Lifetime
- 2004-08-13 AU AU2004270655A patent/AU2004270655B2/en not_active Ceased
- 2004-08-13 EP EP04781131A patent/EP1675864B1/en not_active Expired - Lifetime
- 2004-08-13 JP JP2006523414A patent/JP2007502777A/ja active Pending
- 2004-08-13 AT AT04781131T patent/ATE453653T1/de not_active IP Right Cessation
- 2004-08-13 JP JP2006523413A patent/JP2007502301A/ja active Pending
- 2004-08-13 CA CA002535762A patent/CA2535762A1/en not_active Abandoned
- 2004-08-13 WO PCT/US2004/026393 patent/WO2005016946A2/en not_active Ceased
- 2004-08-13 US US10/918,762 patent/US7238372B2/en not_active Expired - Lifetime
- 2004-08-13 AT AT04809566T patent/ATE404574T1/de not_active IP Right Cessation
- 2004-08-13 CA CA002535584A patent/CA2535584A1/en not_active Abandoned
- 2004-08-13 EP EP04809566A patent/EP1664070B1/en not_active Expired - Lifetime
- 2004-08-13 AU AU2004264421A patent/AU2004264421B2/en not_active Ceased
- 2004-08-13 US US10/918,769 patent/US7566798B2/en not_active Expired - Fee Related
-
2007
- 2007-01-31 US US11/701,907 patent/US7763585B2/en not_active Expired - Fee Related
-
2009
- 2009-07-21 US US12/506,913 patent/US7759510B2/en not_active Expired - Fee Related
-
2010
- 2010-07-13 US US12/835,114 patent/US8247445B2/en not_active Expired - Fee Related
- 2010-07-15 US US12/837,046 patent/US8598230B2/en not_active Expired - Fee Related
-
2011
- 2011-05-23 AU AU2011202386A patent/AU2011202386A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1664070A2 (en) | 2006-06-07 |
| DE602004015811D1 (de) | 2008-09-25 |
| AU2004264421B2 (en) | 2011-02-24 |
| US7763585B2 (en) | 2010-07-27 |
| ATE404574T1 (de) | 2008-08-15 |
| AU2004264421A1 (en) | 2005-02-24 |
| US20050080131A1 (en) | 2005-04-14 |
| WO2005016946A2 (en) | 2005-02-24 |
| AU2011202386A1 (en) | 2011-06-09 |
| AU2004270655B2 (en) | 2011-03-24 |
| US7238372B2 (en) | 2007-07-03 |
| US20050074502A1 (en) | 2005-04-07 |
| US8247445B2 (en) | 2012-08-21 |
| US7566798B2 (en) | 2009-07-28 |
| JP2007502301A (ja) | 2007-02-08 |
| US20080187992A1 (en) | 2008-08-07 |
| JP2007502777A (ja) | 2007-02-15 |
| EP1664070B1 (en) | 2008-08-13 |
| US20100310645A1 (en) | 2010-12-09 |
| EP1675864A2 (en) | 2006-07-05 |
| US20090285884A1 (en) | 2009-11-19 |
| DE602004024909D1 (de) | 2010-02-11 |
| WO2005023824A3 (en) | 2005-06-09 |
| US8598230B2 (en) | 2013-12-03 |
| WO2005023824A2 (en) | 2005-03-17 |
| WO2005016946A3 (en) | 2005-09-29 |
| CA2535584A1 (en) | 2005-02-24 |
| AU2004270655A1 (en) | 2005-03-17 |
| US20100316704A1 (en) | 2010-12-16 |
| US7759510B2 (en) | 2010-07-20 |
| ATE453653T1 (de) | 2010-01-15 |
| EP1675864B1 (en) | 2009-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2004270655B2 (en) | Methods for inhibiting tumor cell proliferation | |
| Turkson et al. | Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity | |
| Turkson | STAT proteins as novel targets for cancer drug discovery | |
| Buettner et al. | Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention | |
| JP6929234B2 (ja) | 医薬共結晶組成物及びその用途 | |
| Nikitakis et al. | Targeting the STAT pathway in head and neck cancer: recent advances and future prospects | |
| US7807662B2 (en) | Platinum IV complex inhibitor | |
| US20100190180A1 (en) | Materials and Methods for Screening, Diagnosis and Prognosis of Conditions Associated With Stat Protein Expression | |
| Nagy et al. | A preferential role for STAT5, not constitutively active STAT3, in promoting survival of a human lymphoid tumor | |
| Turkson et al. | Methods for inhibiting tumor cell proliferation | |
| CA2587779A1 (en) | Platinum complexes for targeted drug delivery | |
| CN106188147B (zh) | 含喹唑啉类配体的Pt配合物及其制备方法和应用 | |
| Kay et al. | Platinum complexes and methods of use | |
| Buettner et al. | STAT proteins as molecular targets for cancer therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |